ROS1 Biomarkers
News and reporting on ROS1 biomarkers.
Avistone Biotechnology to Begin Trial of Next-Generation ROS1/NTRK Inhibitor
The firm will study ANS03 in patients with tumors harboring a ROS1 or NTRK alteration, including those with acquired resistance mutations.
CHMP Recommends BMS's Augtyro for ROS1-Positive NSCLC, NTRK-Positive Tumors
The European Commission will decide whether to approve Augtyro in these two indications in January 2025.
In the TRUST-II trial, 85 percent of ROS1 TKI-naïve NSCLC patients and 62 percent of TKI-pretreated patients responded to the next-generation ROS1 inhibitor.
Lung Cancer Groups Seek Public Comment on Updated Biomarker Testing Guidelines
Updated guidelines recommend certain biomarker tests for early- and late-stage lung cancer at the time of diagnosis.
China's NMPA Approves Zai Lab's Augtyro in ROS1-Positive NSCLC
In a Phase I/II trial, 38 percent of patients who had prior tyrosine kinase inhibitor treatment responded, while the response rate among those who were TKI-naïve was 79 percent.